Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris

Autor: Kragballe, Knud, Austad, J, Barnes, L, Bibby, A, de la Brassinne, M, Cambazard, F, Flemming, C, Heikkilä, H, Jolliffe, D, Peyri, J, Svensson, Å, Toole, J, Wozel, G

Publikováno v: Kragballe, K, Austad, J, Barnes, L, Bibby, A, de la Brassinne, M, Cambazard, F, Flemming, C, Heikkilä, H, Jolliffe, D, Peyri, J, Svensson, Å, Toole, J & Wozel, G 2006, ' A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet ® /Daivobet ® /Taclonex ® ) in the treatment of psoriasis vulgaris ', Br. J. Dermatol., no. 154, pp. 1155-1160 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pure_au_____::721a55b66b3e25ae7eb26da6ffc3dc61
https://pure.au.dk/portal/da/publications/a-52week-randomized-safety-study-of-a-calcipotriolbetamethasone-dipropionate-twocompound-product-dovobetdaivobettaclonex-in-the-treatment-of-psoriasis-vulgaris(93241d50-4fa4-11db-bee9-02004c4f4f50).html

Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity

Autor: Kerkhof, P.C.M. van de, Kragballe, K., Austad, J., Berth-Jones, J., Cambazard, F., Brassinne, M. de la, Ljungberg, A., Murphy, G., Papp, K., Wozel, G.

Publikováno v: European Journal of Dermatology, 16, 167-71
van de Kerkhof, PC, Kragballe, K, Austad, J, Berth-Jones, J, Cambazard, F, de la Brassinne, M, Ljungberg, A, Murphy, G, Papp, K & Wozel, G 2006, ' Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity ', Eur J Dermatol, vol. 16, no. 2, pp. 167-71 .
European Journal of Dermatology, 16, 2, pp. 167-71

Contains fulltext : 50118.pdf (Publisher’s version ) (Closed access) Psoriasis treatment is highly individualized. Although a standardized assessment of psoriasis severity for clinical practice may be theoretically advantageous for the purposes of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::18d32eb679e7bc8388c2a5db075f5b6d
http://hdl.handle.net/2066/50118

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.